Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.

This study investigates several potential factors that could determine durable therapeutic response for patients with myeloma who receive BCMA CAR T-cell therapy. The authors conclude that there is a dynamic relationship among “endogenous T, CAR T, myeloid/dendritic cells, and tumor compartments” that could be further investigated regarding potentially prognostic factors.